11-68939671-T-G
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BP4_ModerateBS1BS2
The NM_002180.3(IGHMBP2):āc.2922T>Gā(p.Asp974Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00189 in 1,612,916 control chromosomes in the GnomAD database, including 5 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002180.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IGHMBP2 | NM_002180.3 | c.2922T>G | p.Asp974Glu | missense_variant | 15/15 | ENST00000255078.8 | NP_002171.2 | |
IGHMBP2 | XM_017017670.3 | c.1911T>G | p.Asp637Glu | missense_variant | 11/11 | XP_016873159.1 | ||
IGHMBP2 | XM_005273975.4 | c.1794T>G | p.Asp598Glu | missense_variant | 8/8 | XP_005274032.1 | ||
IGHMBP2 | XM_011544994.2 | c.1689T>G | p.Asp563Glu | missense_variant | 8/8 | XP_011543296.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IGHMBP2 | ENST00000255078.8 | c.2922T>G | p.Asp974Glu | missense_variant | 15/15 | 1 | NM_002180.3 | ENSP00000255078.4 |
Frequencies
GnomAD3 genomes AF: 0.00140 AC: 213AN: 152034Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.00104 AC: 257AN: 247262Hom.: 1 AF XY: 0.00106 AC XY: 142AN XY: 134116
GnomAD4 exome AF: 0.00195 AC: 2842AN: 1460764Hom.: 4 Cov.: 31 AF XY: 0.00185 AC XY: 1346AN XY: 726662
GnomAD4 genome AF: 0.00140 AC: 213AN: 152152Hom.: 1 Cov.: 33 AF XY: 0.00129 AC XY: 96AN XY: 74376
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 01, 2014 | - - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The IGHMBP2 p.Asp974Glu variant was identified 1 of 58 proband chromosomes (frequency: 0.017) from an infant with distal spinal muscular atrophy with respiratory distress type 1 (SMARD1) who carried another variant of uncertain significance in the IGHMBP2 gene (Grohmann_2003_PMID: 14681881). The variant was identified in dbSNP (ID: rs147674615) and ClinVar (classified as uncertain significance by Athena diagnostics, ARUP laboratories, EGL Diagnostics, and Illuminal, and as likely benign by Invitae). The variant was identified in control databases in 304 of 278604 chromosomes (1 homozygous) at a frequency of 0.001091 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 239 of 126884 chromosomes (freq: 0.001884), Other in 12 of 7070 chromosomes (freq: 0.001697), African in 21 of 24426 chromosomes (freq: 0.00086), Latino in 28 of 35132 chromosomes (freq: 0.000797), European (Finnish) in 3 of 24636 chromosomes (freq: 0.000122) and South Asian in 1 of 30452 chromosomes (freq: 0.000033), but was not observed in the Ashkenazi Jewish or East Asian populations. The p.Asp974 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 15, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 13, 2023 | The IGHMBP2 c.2922T>G; p.Asp974Glu variant (rs147674615) is reported in the literature in individuals with respiratory distress and/or sudden death (Grohmann 2003, Salfati 2019, Torkamani 2016), and in large cohorts of individuals with Charcot-Marie-Tooth disease or peripheral neuropathy (Antoniadi 2015, Volodarsky 2021). This variant is also reported in ClinVar (Variation ID: 194494), and is found in the general population with an overall allele frequency of 0.11% (304/278604 alleles, including a single homozygote) in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.664). Due to limited information, the clinical significance of this variant is uncertain at this time. References: Antoniadi T et al. Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield with unexpected phenotype-genotype variability. BMC Med Genet. 2015 Sep 21;16:84. PMID: 26392352. Grohmann et al. Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Ann Neurol. 2003 Dec;54(6):719-24. PMID: 14681881. Salfati EL et al. Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. Genome Med. 2019 Dec 17;11(1):83. PMID: 31847883. Torkamani A et al. Molecular Autopsy for Sudden Unexpected Death. JAMA. 2016 Oct 11;316(14):1492-1494. PMID: 27727376. Volodarsky M et al. Comprehensive genetic sequence and copy number analysis for Charcot-Marie-Tooth disease in a Canadian cohort of 2517 patients. J Med Genet. 2021 Apr;58(4):284-288. PMID: 32376792. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2024 | IGHMBP2: BS1 - |
Charcot-Marie-Tooth disease Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Genetics Laboratory, London Health Sciences Centre | - | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 27, 2023 | The c.2922T>G (p.D974E) alteration is located in exon 15 (coding exon 15) of the IGHMBP2 gene. This alteration results from a T to G substitution at nucleotide position 2922, causing the aspartic acid (D) at amino acid position 974 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Autosomal recessive distal spinal muscular atrophy 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The IGHMBP2 c.2922T>G (p.Asp974Glu) missense variant has been reported in one study in which it is found in a compound heterozygous state in one individual with spinal muscular atrophy (Grohmann et al. 2003). Control data are unavailable for this variant, which it is reported at a frequency of 0.00163 in the European American population of the Exome Sequencing Project. The evidence for this variant is limited. The p.Asp974Glu variant is therefore classified as a variant of unknown significance but suspicious for pathogenicity for spinal muscular atrophy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Charcot-Marie-Tooth disease axonal type 2S Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 11, 2018 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 02, 2020 | - - |
Autosomal recessive distal spinal muscular atrophy 1;C4015349:Charcot-Marie-Tooth disease axonal type 2S Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at